MARKETS / VSBC
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP
Vitaspring Biomedical Co. Ltd. VSBC
10 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-415,368
Growth
—
Revenue, FY2025 · full 10-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -0.4
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2021 · Operating 20.1% · Net 16.2%
ROE
FY2021 · ROE 108.7%
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | −0.0 | −0.0 | · | · | · | · | · |
| EPS, diluted $ | 0.00 | 0.00 | −0.01 | −0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | 108.7 | 441.4 | · | · | · | −1.5 |
| Shares out B | 0.21 | 0.21 | · | 0.15 | 0.12 | 0.21 | 0.01 | 0.01 | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 6 failures in 42 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 53 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente6 failures
ActivityServices-Commercial Physical & Biological Research
Listed onnot stated in the filings
Incorporated inNevada
Fiscal year endsJanuary 31
SEC categorysmaller reporting company
Data on record since2016